Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Gastric Antisecretory Drug Market Size, Value And Growth Trajectory Through 2030
The gastric antisecretory drug market has seen significant growth in recent years. Its value is anticipated to increase from $15.63 billion in 2025 to $16.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. This historic expansion is largely due to the high prevalence of acid-related disorders, a rise in gastroesophageal reflux disease diagnoses, the broadening reach of hospital pharmacies, the extensive use of H2 receptor antagonists, and an upward trend in self-medication.
The gastric antisecretory drug market size is anticipated to experience robust expansion in the coming years. By 2030, this market is projected to reach $20.7 billion, demonstrating a compound annual growth rate (CAGR) of 5.8%. This projected increase during the forecast period is primarily driven by factors such as an aging global population, the rise in gastric conditions linked to stress, the broadening of over-the-counter (OTC) medication markets, heightened health consciousness, and the development of safer, enduring treatment options. Key developments expected to shape the market during this period involve the increasing adoption of proton pump inhibitors, a growing need for sustained acid suppression, a shift towards oral drug formulations, wider over-the-counter access, and a greater emphasis on managing gastrointestinal diseases.
Get A Free Sample Report With In-Depth Market Insights:
Gastric Antisecretory Drug Market Growth Factors Behind Sustained Expansion
The increasing occurrence of gastrointestinal disorders is anticipated to propel the expansion of the gastric antisecretory drug market in the coming years. These conditions impact the digestive tract, including the stomach, intestines, and associated organs, leading to symptoms such as pain, bloating, and altered bowel movements. The rise in gastrointestinal disorders is primarily fueled by unhealthy dietary practices, where excessive intake of processed foods and insufficient fiber contribute to imbalances in gut microbiota and impaired digestion. Gastric antisecretory drugs are essential because an excess of stomach acid can damage the protective lining of the gastrointestinal tract, resulting in irritation or injury, which these medications help prevent by reducing acid production. For instance, in June 2025, according to the Turkish Journal Of Gastroenterology, a Turkey-based journal, 6.9 million individuals globally suffering from inflammatory bowel disease (IBD) currently. Therefore, the growing prevalence of gastrointestinal disorders will boost the growth of the gastric antisecretory drug market.
Gastric Antisecretory Drug Market Segment Breakdown: Which Categories Lead On Revenue?
The gastric antisecretory drug market covered in this report is segmented –
1) By Drug Class: Proton Pump Inhibitors (PPIs), H2 Receptor Antagonists, Antacids, Prostaglandin Analogs
2) By Route Of Administration: Oral, Intravenous
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By Application: Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Zollinger-Ellison Syndrome, Other Applications
Subsegments:
1) By Proton Pump Inhibitors (PPIs): Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole, Dexlansoprazole
2) By H2 Receptor Antagonists: Ranitidine, Famotidine, Cimetidine, Nizatidine
3) By Antacids: Magnesium Hydroxide, Calcium Carbonate, Aluminum Hydroxide, Sodium Bicarbonate, Combination Antacids
4) By Prostaglandin Analogs: Misoprostol, Enprostil
Gastric Antisecretory Drug Market Industry Trends Fueling Future Revenue Growth
Leading companies in the gastric antisecretory drug market are concentrating on developing advanced products, such as antisecretory compounds, to provide extended relief. Antisecretory compounds are substances designed to diminish or suppress the secretion of bodily fluids, particularly gastric acid, by acting on specific cellular pathways or receptors. For instance, in June 2024, Akums Drugs and Pharmaceuticals, an India-based pharmaceutical company, launched Rabeprazole + Levosulpiride SR Capsules, a new formulation intended for Gastrointestinal patients. This formulation uniquely integrates rabeprazole sodium, a powerful antisecretory agent that selectively inhibits the H?/K? ATPase in gastric parietal cells, with levosulpiride, which is known for its central antidopaminergic and antiemetic properties. The capsule delivers 40 mg of enteric-coated rabeprazole and 75 mg of sustained-release levosulpiride, ensuring a targeted and prolonged therapeutic action. Its dual mechanism addresses both the suppression of acid and the regulation of gastrointestinal motility.
Gastric Antisecretory Drug Market Leading Players And Competitive Positioning
Major companies operating in the gastric antisecretory drug market are Pfizer Inc., Bayer AG, AstraZeneca plc, Takeda Pharmaceutical Company Ltd., Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Chemo Biological, Spansules Pharmatech Pvt. Ltd., Phoenix Biologicals Pvt. Ltd., Centurion Remedies Private Limited, Solitaire Pharmacia Pvt. Ltd., Shreeji Pharma International, Estrellas Life Sciences Private Limited, 3s Corporation, Actiza Pharmaceutical Private Limited, Lark Laboratories, Cytonova Labs International Private Limited, Luckys Pharma Lab Pvt. Ltd., Lexicare Pharma Pvt. Ltd., Mustcure Healthcare LLP
View The Full Gastric Antisecretory Drug Market Report:
Gastric Antisecretory Drug Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the gastric antisecretory drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric antisecretory drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
